Recent randomized trials returning SLCO1B1 genotype information for statin therapy specifically have observed short-term improvements in statin reinitiations and reduced LDL-C [23] and have demonstrated an absence of negative effects on CVD prevention and potential aversion to simvastatin by prescribing physicians for patients at increased genetic risk of SAMS in a primary care setting [24]. Here, SLCO1B1 is linked to short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.